Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (VKTX)
NASDAQ:VKTX
Holding VKTX?
Track your performance easily
VKTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.21 - $99.41
Previous Close$49.11
Volume4.20M
Average Volume (3M)4.18M
Market Cap
$5.53B
Enterprise Value$4.60B
Total Cash (Recent Filing)$930.44M
Total Debt (Recent Filing)$1.24M
Price to Earnings (P/E)―
Beta2.77
Next Earnings
Feb 05, 2025EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding111,436,384
10 Day Avg. Volume5,884,285
30 Day Avg. Volume4,175,441
Standard Deviation0.37
R-Squared0.02
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)6.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-62.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-42.80
Forecast
1Y Price Target
$116.56Price Target Upside126.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Viking Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNew efficacy analyses from the Ph2 VENTURE study show that the stellar placebo-adjusted weight loss observed at week 13 was maintained from week 12-16, with 83% of patients maintaining their weight loss out to 19 weeks.
Financial PositionCompany has a strong cash position, with cash, cash equivalents and short-term investments of approximately $930 million, sufficient to fund through Phase 3 subcutaneous and beyond Phase 2 oral studies and other clinical developments.
Product DifferentiationThere is potential for monthly maintenance dosing of VK2735, which could differentiate VKTX in the highly competitive market.
Bears Say
Competitive EnvironmentRoche's CT-388 program shows high rates of nausea, diarrhea, vomiting, and constipation, which may limit its dose optimization.
Financial PerformanceTotal operating expenses were slightly higher than expected due to G&A expenses.
Stock PerformanceThe stock is trading down ~10% despite positive data, possibly due to profit-taking after a substantial rise in value.
---
Ownership Overview
2.71% Insiders
26.66% Mutual Funds
16.56% Other Institutional Investors
40.00% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VKTX FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was $11.21 and its highest was $99.41 in the past 12 months.
What is Viking Therapeutics’s market cap?
Currently, no data Available
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Feb 05, 2025 which is in 75 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Oct 23, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.243 by $0.023.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -$0.28.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 111,436,386 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.243. Following the earnings report the stock price went up 21.245%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Among the largest hedge funds holding Viking Therapeutics’s share is Viking Global Investors LP. It holds Viking Therapeutics’s shares valued at 86M.
---
Viking Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$116.56 (126.20% Upside)
$116.56 (126.20% Upside)
Blogger Sentiment
Bullish
VKTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 13.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $137.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
335.75%
12-Months-Change
Fundamentals
Return on Equity
-15.50%
Trailing 12-Months
Asset Growth
145.09%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
---
VKTX Earnings Call
Q3 2024
0:00 / 0:00
---
VKTX Stock 12 Month Forecast
Average Price Target
$116.56
▲(126.20% Upside)
Technical Analysis
Best Analysts Covering VKTX
1 Year
1 Year Success Rate
13/18 ratings generated profit
1 Year Average Return
+196.12%
reiterated a buy rating 30 days ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 72.22% of your transactions generating a profit, with an average return of +196.12% per trade.
---